Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

CVS Health Corporation (NYSE:CVS)

• Dividend Yield: 5.71%
• Truist Securities analyst David Macdonald reiterated a Buy rating and cut the price target from $76 to $67 on Nov. 20. This analyst has an accuracy rate of 66%.
• UBS analyst Kevin Caliendo maintained a Neutral rating and raised the price target from $60 to $62 on Nov. 7. This analyst has an accuracy rate of 70%.
• Recent News: On Monday, CVS Health announced early results of maximum tender offer and election of early settlement.
• Benzinga Pro's real-time newsfeed alerted to latest CVS news.

Bristol-Myers Squibb Company (NYSE:BMY)

• Dividend Yield: 4.44%
• B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $63 on Dec. 10. This analyst has an accuracy rate of 61%.
• Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $55 to $60 on Nov. 12. This analyst has an accuracy rate of 70%.
• Recent News: On Dec. 13, Bristol Myers Squibb said its Board of Directors declared a quarterly dividend of 62 cents per share on the $0.10 par value common stock of the company.
• Benzinga Pro's real-time newsfeed alerted to latest BMY news.

AbbVie Inc. (NYSE:ABBV)

• Dividend Yield: 3.82%
• B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $191 on Dec. 10. This analyst has an accuracy rate of 61%.
• Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $206 on Nov. 22. This analyst has an accuracy rate of 74%.
• Recent News: On Dec. 13, AbbVie announced plans to acquire Nimble Therapeutics.
• Benzinga Pro’s charting tool helped identify the trend in ABBV stock.

Read More:

• How To Earn $500 A Month From Worthington Enterprises Stock Ahead Of Q2 Earnings